BATS BZX Real-Time Price
As of 1:33pm ET
| -1.89 / -1.48%|
The 18 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 151.50, with a high estimate of 220.00 and a low estimate of 56.00. The median estimate represents a +20.81% increase from the last price of 125.40.
The current consensus among 19 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.